Bovine TB

Baroness McIntosh of Pickering Excerpts

Thursday 3rd April 2014 Commons Chamber

[Mr Paterson]

Thank you, Madam Deputy Speaker.

The position is very simple. The pilots were set up last year. The hon. Lady asked about the roll-out of our programme. We made clear that we would learn lessons: the IEP report contained some very helpful advice, and we will adopt it. We are acting responsibly by maintaining the two existing cull areas. The hon. Lady mentioned the risk of increasing disease. My chief veterinary officer, Nigel Gibbens, has stated emphatically that ending culling in the two existing areas would greatly increase the risk of the disease, and his very strong scientific advice is that it should continue.

As for Wales, I am delighted that there has been a reduction in the disease there. According to the farmers in Wales to whom I have spoken, it may be due to the spike that occurred when annual testing was introduced recently. Given that the vaccination trial has only been taking place for two years in 1.5% of the land in Wales, to attribute it to vaccination is laughable.

The hon. Lady raised the issue of humaneness. The IEP report shows that 68 out of 69 badgers died virtually instantly. However, there are clear lessons to be learned on how we can improve humaneness, which we are happy to adopt.

The hon. Lady mentioned the number culled last year. I remind her that during the first year of the randomised badger culling trial that took place under the Government she supported, only 32%, 37% and 39% respectively were culled in three of the trial areas, but in those areas the culls did contribute to disease reduction later on.

The hon. Lady also mentioned cost. We are heading for a bill of £1 billion. We simply must address the disease in cattle and in wildlife, as has happened in every other country to which I referred in my statement. [Interruption.] I have already touched on the subject of Wales and vaccination, but I repeat for the benefit of Opposition Front Benchers who are chuntering from a sedentary position that it is not credible to attribute the reduction in Wales to a two-year vaccination programme that took place in 1.5% of the geographical area of Wales.

The hon. Lady came up with a few ideas, and I am delighted to say that we are in agreement on all of them. On badger vaccination, I have announced that we want to establish a buffer zone at the edges of the worst affected areas, because treating healthy badgers with the current badger vaccine—however difficult it is to deploy, given that a third of badgers are trap-shy—may help to build up a buffer zone, and that is worth doing. Sadly, injecting diseased badgers in the hot-spot areas with cattle vaccine will not reduce the incidence of the disease. I think that we agree on that.

The hon. Lady mentioned risk-based trading in connection with for cattle measures. We have already introduced that. I was very clear about this in my statement. If she looks at the strategy, she will see there are considerable new measures there, which are much stricter on cattle risk-based trading. It would be good if the hon. Lady went through our response to the independent panel so she sees that we are adopting its proposals, and went through our strategy, which shows that we are looking to bring in a whole range of tools. She should not just focus on culling of diseased badgers, although that is an important part, as we are bringing in a whole range of other measures, and down the road, as I made clear in the statement, I really do want to get to the position where we are leading the world on developing a cattle vaccine and where, above all, we can get better diagnostic techniques—possibly DNA systems—which can diagnose disease in cattle and in badgers.

[Miss Anne McIntosh (Thirsk and Malton) (Con)]

I welcome the strategy and the fact that the Government are going to implement the panel recommendations. The public will be very alarmed that TB is now spreading through pets, and I hope the Secretary of State can address that. I urge him to give the House an assurance on the date when the field trials will take place and the timetable for the legislative changes, and will he also look favourably on the sterilisation programme which is being developed in my constituency?

[Mr Paterson]

I am grateful to the Chairman of the Select Committee for her questions. On the development of cattle vaccine, which I think she was asking about, we do not have an immediate timetable when we can start. These are complex, difficult trials and we need to work out, working closely with the European Commission, how we bring them in in practical terms. A major issue is what we do with the animals that may have been treated, because we have to decide whether they can go for human consumption or not.